Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma (IPi-504-01)

Infinity Pharmaceuticals

Status and phase

Completed

Phase 1

Conditions

Multiple Myeloma

Treatments

Drug: IPI-504

Study type

Interventional

Funder types

Industry

Identifiers

NCT00113204

IPI-504-01

Details and patient eligibility

About

This is a phase 1 clinical trial to find the safe, maximum tolerated dose of IPI-504 in patients with relapsed and/or relapsed, refractory multiple myeloma. This study will examine how IPI-504 is absorbed, distributed, metabolized, and eliminated by the body. The study will also evaluate potential anti-tumor activity of IPI-504.

Full description

IPI-504 is a novel small molecule inhibitor of heat shock protein 90 (Hsp90), an emerging and recently identified target for cancer therapy. Hsp90 is a protein chaperone that plays a central role in regulating protein homeostasis. Hsp90 regulates the stability of key proteins (called "client proteins") and keeps them in the appropriate three dimensional shape so they can perform their cellular functions. In addition, many of the proteins stabilized by Hsp90 are oncoproteins and cell-signaling proteins important in cancer cell proliferation and cancer cell survival. Thus Hsp90, a single molecular target that is a central integrator of multiple pathways important to cancer, is an ideal novel target for oncologic therapy. Selective inhibition of Hsp90 will affect multiple downstream mechanisms to disrupt tumor growth and selectively kill cancer cells. The anti-neoplastic effects of Hsp90 inhibition have been demonstrated both in vitro and in vivo for a variety of different hematologic and solid tumors including multiple myeloma.

Enrollment

18 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Diagnosis of relapsed or relapsed, refractory disease
Age is greater or equal to 18 years at the time of signing the informed consent
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
Ability to adhere to the study visit schedule and all protocol requirements
Voluntarily sign an informed consent
All baseline studies must be completed for determining eligibility within 21 days of study enrollment
Women of child-bearing potential (WCBP) defined as a sexually mature woman who has not undergone a hysterectomy or who has not been naturally post-menopausal for at least 24 consecutive months must have a negative serum or urine pregnancy test prior to each cycle of treatment
All WCBP and all sexually active male patients must agree to use adequate methods of birth control throughout the study

Exclusion criteria

Disease specific treatment within the previous 3 weeks including use of chemotherapy that is known to be active or may be active against multiple myeloma
Previous treatment with 17-AAG, DMAG, or other known Hsp90 inhibitor
Participation in any investigational drug study within 3 weeks preceding start of treatment for conventional small molecule therapy or 4 weeks preceding the start of treatment for biologic or vaccine therapy; concurrent radiation therapy is not permitted
Concomitant use of corticosteroids may not exceed prednisone 10 mg per day with the exception of pre-medication for transfusion of blood products and topical application
Concurrent treatment with any agent that alters CYP3A activity (unless maintained on stable dose)
Baseline QTc >450
NYHA class 3 or 4 congestive heart failure
Left Bundle Branch Block
Mycardial infarction or active ischemic heart disease within 6 months
Grade 3 or greater peripheral neuropathy
Renal insufficiency, serum creatinine >2x upper limit of normal (ULN)
Platelets < 30,000 mm3 or refractory to transfusion and unable to be maintained > 50,000 mm3
AST and / or ALT > 2.0x ULN
ANC <1,000 cells/mm3
Hemoglobin < 8.0 g/dL
Presence of active infection or systemic use of antibiotics within 72 hours of treatment
WCBP who are breast feeding
Significant co-morbid condition or disease which in the judgment of the investigator would place the patient at undue risk or interfere with the study (e.g. cardiac disease such as acute coronary syndrome or unstable angina within 6 months, New York Heart Association (NYHA) class 2 or greater congestive heart failure (CHF), uncontrolled hypertension, arrhythmia requiring medication or mechanical control, chronic obstructive pulmonary disease (COPD), cirrhotic liver disease, or other conditions)